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Background: EUR-1008 (Zenpep™ [pancrelipase]) is a new, enteric-coated, porcine-derived pancreatic enzyme product (PEP) developed for the
treatment of cystic fibrosis (CF) patients with malabsorption associated with exocrine pancreatic insufficiency (EPI). Unlike currently marketed PEPs,
EUR-1008 contains the label-claimed lipase content. Safety and efficacywere assessed in younger (b7 years) and older (≥7 years) CFpatientswithEPI.
Methods: Two multicenter studies were conducted: a randomized, double-blind, placebo-controlled, crossover trial in patients ≥7 years of age
(N=34) and a supplemental, open-label study in children b7 years of age (N=19). Use of anymedications altering gastric pH/motility was prohibited
during the studies. Outcome measures in the randomized trial included changes in the coefficient of fat absorption (CFA), coefficient of nitrogen
absorption (CNA), and signs/symptoms of malabsorption for EUR-1008 vs. placebo. Outcome measures in the supplemental study included safety
and response (defined as no steatorrhea and no overt signs/symptoms of malabsorption) to EUR-1008 vs. previous enzyme treatment.
Results: In the randomized trial, EUR-1008 treatment compared to placebo resulted in a significantly highermeanCFA (88.3%vs. 62.8%, respectively) and
CNA (87.2% vs. 65.7%, respectively) (both pb0.001) and reduced the incidence of malabsorption signs and symptoms in 32 evaluable patients. In the
supplemental study, 11 of 19 patients met the criteria for responder with EUR-1008 at the end of the study vs. 10 of 19 patients at screening (previous PEP),
and improvements in clinical symptoms were reported with EUR-1008 treatment. EUR-1008 was safe and well tolerated, and no serious drug-related AEs
were reported in either study.
Conclusions: EUR-1008was safe, well tolerated, and effective in CF patients of all ages with EPI-associatedmalabsorption in two clinical trials. Treatment
led to clinically and statistically significant improvements in CFA and CNA in the randomized study, and control of malabsorption and clinical symptoms in
both studies.
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Exocrine pancreatic insufficiency (EPI) is defined as fecal
elastase b100 µg/g in the stool [1], and occurs in approximately
85% of cystic fibrosis (CF) patients [2,3], resulting in impaired
digestion and decreased absorption of nutrients [3]. Signs and
symptoms of EPI include malabsorption, steatorrhea, bloating,
pain, and flatus, which develop soon after birth. Poor nutritional
status associated with untreated or insufficiently treated EPI
impairs growth, compromises pulmonary outcomes, weakens
immune response, and shortens the life expectancy of CF
patients [4–11]. The use of oral pancreatic enzyme products
(PEPs) significantly improves the nutritional status of CF
patients, which is closely linked to improvements in lung
function [4–11] as well as the increased life expectancy that has
been achieved by CF patients over the previous decades [12,13].
Therefore, improving the nutritional status of patients with CF
and EPI is a goal of treatment, and supplementation with PEPs
at meals and snacks is the mainstay of therapy for EPI.
PEPs are typically a mixture of porcine-derived pancrelipase,
which is a combination of three enzymes: lipase, amylase and
protease. Current gastric acid-protected products are designed to
release enzymes in the upper small intestine to aid digestion and
improve nutrient absorption. Among currently marketed PEPs for
EPI, great variability in the amount of enzymes included in each
capsule has been noted [14–17], due in part to the manufacturer
practice of overfilling capsules to account for enzyme degradation
that occurs over the course of the product's shelf life. Variability
in the product's enzyme content can lead to inconsistent
therapeutic effects by either providing too much or too little of
the required enzymes,whichmay lead to the suboptimal treatment
of the patient's EPI. In addition, overfilled products may increase
the risk of fibrosing colonopathy, which has been associated in
some reports with long-term exposure to high-dose pancreatic
enzyme replacement therapy [18–20]. Most PEPs were devel-
oped before current United States Food and Drug Administration
(FDA) New Drug Approval (NDA) requirements were enacted
[21]. The possible safety risk posed by high-dose enzyme therapy,
particularly fibrosing colonopathy [18–20], in combination with
the issue of enzyme overfill, recently prompted the FDA to
require the manufacturers of PEPs to demonstrate drug efficacy
and safety in randomized, placebo-controlled trials before
approval [21]. Guidelines from the FDA now require that new
PEPs be formulated tomeet the label-claimed enzyme content and
demonstrate safety and efficacy in human clinical trials [21],
including trials in young children. Although there appear to be no
age-related issues with PEP treatment in children b7 years of age
[22–26], little safety data has been published in this patient group.
The majority of literature on PEP usage in cystic fibrosis has
focused on adolescents and adults.
EUR-1008 (Zenpep™ [pancrelipase] Eurand S.p.A., Milan,
Italy) is a new, porcine-derived, enteric-coated PEP designed
with a stable formulation to ensure that the product contains the
label-claimed enzyme content, per the 2006 U.S. FDA guide-
lines for EPI drug products [21]. Two clinical trials were
designed to evaluate the safety and efficacy of EUR-1008 for
the treatment of EPI-associated malabsorption in patients withCF: a randomized, double-blind, placebo-controlled study in
patients ≥7 years of age and a supplemental study in patients
b7 years of age.
2. Materials and methods
The randomized, double-blind, placebo-controlled, two-treat-
ment, crossover design, multicenter, phase III trial was performed
at 12 U.S. sites in older patients with CF and EPI, while the
supplemental, open-label, multiple-dose, multicenter, phase III
study was conducted at 11 U.S. sites in younger children with CF
and EPI.
2.1. Protocol development and informed consent
The Cystic Fibrosis Foundation (CFF) and the CF Ther-
apeutics Development Network (TDN) worked with the sponsor
to create both study protocols, and the protocols were approved
by both the TDN and the Institutional Review Board (IRB) of
each participating study site. The study designs were reviewed
and approved by the CFF Data Safety Monitoring Board
(DSMB) prior to implementation. Written informed consent was
obtained from all adult patients (≥18 years of age) or parents/
guardians of patients b18 years of age, and appropriate assent
was obtained from all children per site-specific IRB policy.
2.2. Study drug and dosage
In both studies, the active study drug was provided in orally-
administered capsules containing enteric-coated microspheres
of porcine enzyme concentrate, which included lipase, amylase,
and protease. The placebo in the randomized trial consisted of
capsules filled with cellulose microcrystalline spheres, which
were identical in appearance to the capsules containing active
treatment.
Patients in the randomized trial could receive any of the four
dosage formulations of EUR-1008 (5000, 10,000, 15,000, and
20,000 USP units of lipase/capsule), or any combination of these
dosages, at the investigator's discretion during the study. The
suggested starting dose for treatment in the randomized trial was
1000 lipase units/kg/meal, and the targeted maximum dose was
≤2500 lipase units/kg/meal and ≤4000 lipase units/gram fat/day.
Patients in the supplemental study were administered the
formulation containing 5000 USP units of lipase/capsule and
were to receive approximately 2000 lipase units/kg/meal of the
EUR-1008 formulation during the study. The starting dose for
treatment in the supplemental study was based on the dosage of the
patient's previous pancreatic enzyme therapy. The doses of EUR-
1008 in both studies were given in accordance with the 1995 joint
recommendations of the FDA and the U.S. Cystic Fibrosis
Foundation [27], as well as the suggestion of FitzSimmons et al.
[20], based on a case-control study of fibrosing colonopathy and
PEP use, to limit maximum daily doses to b10,000 lipase units/kg.
In both studies, the dose was adjusted at the investigator's
discretion during the dose stabilization periods based on clinical
symptoms of malabsorption as reported by the patient and/or
parents/guardians to determine the individual appropriate dose
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The dose could be adjusted in steps up to 25% of the starting
dose, rounded to the nearest 5000 lipase units/capsule
(randomized trial) or content of a half capsule (supplemental
study). Patients generally received three doses/day with their
meals and a snack dose, as determined by the patient or parent/
guardian. In the supplemental study, the capsules could be
opened and the contents sprinkled on appropriate food when-
ever needed.
2.3. Patient populations and inclusion/exclusion criteria
Patients with a confirmed diagnosis of CF (sweat chloride
N60 mmol/L or two CF-causing mutations) and EPI (fecal
elastase of b100 µg/g stool) and age ≥7 years (randomized
trial) or b7 years (supplemental study) were eligible to enroll.
Patients were required to be clinically stable with no evidence of
acute upper or lower respiratory tract infection, and with good
nutritional status (body mass index [BMI]≥20 kg/m2 for
patients age 18 years and older; BMI N25th percentile for
patients age 2–17 years; or height/weight ratio Nthe 25th
percentile for children b2 years of age [28]) and a body weight
≤70 kg. Patients were also judged by their CF physician to be
candidates for a change from their existing pancreatic enzyme
treatment.
Medications with the potential to affect gastric motility or
stomach pH (i.e., proton pump inhibitors [PPIs], histamine-2
[H2] blockers, motility agents, buffering agents, laxatives
[including mineral oil, castor oil, and MiraLAX® (polyethylene
glycol, Schering-Plough, Kenilworth, NJ)], agents for gastric
ulcers, synthetic fat substitutes, fat-blocking nutritional supple-
ments) were not permitted during either study, and patients who
were unable to discontinue the use of such medications over the
course of the study were excluded. Other key exclusion criteria
for both studies included: history or diagnosis of fibrosing
colonopathy or distal intestinal obstruction syndrome (DIOS);
hyperuricemia or hyperuricosuria; hepatic insufficiency; history
or current screening evaluation of hyperglycemia or CF-related
diabetes; forced expiratory volume (FEV) b30% of predicted
FEV1 at Screening (randomized study only); use of an acute
dose of immunosuppressive drugs within the two weeks prior to
the study, oral corticosteroids, or antibiotics; history of organ
transplant or bowel surgery; any respiratory condition requiring
hospitalization or intensive pulmonary treatment during the
study (supplemental study only); use of an enzyme preparation
in excess of 10,000 lipase units/kg/day; expected inability to
tolerate the washout period and/or placebo treatment (rando-
mized study only); or allergy to pork or porcine-derived PEPs.
2.4. Study design and conduct
The study designs are shown in Figs. 1 (randomized study)
and 2 (supplemental study). In both studies, after the informed
consent/assent process was completed, subjects were screened
at an outpatient visit. If the inclusion/exclusion criteria were
met, the patients either underwent a two-day washout period
from their current EPI medications (randomized study) or werechanged from their existing PEP to EUR-1008 without a
washout period (supplemental study) and were then titrated/
stabilized on EUR 1008 before entering their respective EUR-
1008 treatment period. Patients in both studies entered the dose
titration/stabilization period using an enzyme dose considered
by the investigator to be comparable to that used by the patient
prior to study entry. The dose of EUR-1008 was then titrated by
the investigator to maintain control of the clinical symptoms of
EPI. The procedure for dose stabilization in the randomized
study was the same regardless of whether the patient was
randomized to start the first double-blind treatment period on
active drug or placebo. Patients discontinued the use of any
medications/foods that alter intestinal motility, gastric pH, fat
absorption, or PEP activity the evening prior to entering the
dose stabilization period. Patients were otherwise instructed not
to change their CF care regimen components during the study,
such as use of vitamin supplementation, except as stated in
inclusion/exclusion criteria. During both studies, all patients
were to consume a standard CF-recommended diet (45% of
calories as fat, 20% as protein, and 35% as carbohydrate). A
dietician reviewed the criteria for the CF diet with patients and/
or their parents/guardians prior to the patient beginning the
study.
In the randomized study, subjects were randomized to EUR-
1008 or placebo after dose titration/stabilization using a balanced
block randomization for sequence generated by an independent,
unblinded statistician who was not otherwise involved in the
study. Randomization assignments were obtained centrally and
were not stratified by site or other factors. The order of treatments
(placebo→EUR-1008 or EUR-1008→placebo) was determined
by the initial randomization scheme. After randomization,
patients were treated with EUR-1008 or placebo for one week.
A 72-hour stool collection, requiring a 3- to 5-day hospitalization
visit during which dietary fat intake was strictly controlled, was
completed over the last three days of treatment. Treatment was
followed by an open-label normalization period during which
patients were stabilizedwith EUR-1008 at the dose determined by
the investigator to be optimal during the earlier dose titration/
stabilization period. At the completion of this first normalization
period, patients were crossed over to the alternative treatment
(EUR 1008 or placebo) with a second 3- to 5-day inpatient
hospitalization to complete the second 72-hour stool collection.
After hospital discharge, there was a second open-label normal-
ization period with EUR-1008, ending with a final end of study
evaluation after seven days of open-label treatment were
completed. Patients were on the study drug at all times except
during the washout period and the blinded placebo period of the
study.
During both inpatient hospitalization periods of the randomized
study, a controlled diet requiring a minimum of 100g of fat was
maintained. During these periods, all food intake was recorded by
the study staff at the site and reviewed by a site dietician prior to
being submitted for central dietary analysis and the nursing staff
dispensed all study medications to patients at meals and snacks
using the predetermined optimal dose. The study staff monitored
compliance with the predetermined optimal dose (determined
by the investigator during dose titration/stabilization) of study
Fig. 1. Flow of the randomized study comparing EUR-1008 to placebo in patients age ≥7 years. The study included a washout period prior to open-label dose titration/
stabilization, followed by randomized treatment, an open-label normalization period, crossover treatment, and a second open-label normalization period prior to study end.
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evaluation periods using pill counts and the dietary records
maintained by patients or their parents/guardians during this time.
Prior to admission and throughout the course of the ran-
domized study, patients or their parents/guardians maintained a
diary of all food consumed, all medications taken (including eachdose of EUR-1008 or placebo taken with each meal or snack), the
frequency and characteristics of all stools, and signs and
symptoms related to EPI malabsorption (pain, bloating, and
flatulence, including severity: mild, moderate, or severe).
In the supplemental study, patients first entered a screening
period of up to 14 days, during which they continued with their
Fig. 2. Flow of the open-label, supplemental study in children age b7 years.
During a screening period of up to 14 days, patients continued taking their previous
pancreatic enzyme product (PEP), which they discontinued, along with any
medications altering gastric pH or motility, upon entering the study. The study
period consisted of a 7-day dose stabilization period using EUR-1008, followed by
a 7-day treatment period with the study drug. PEP: pancreatic enzyme product.
409J.L. Wooldridge et al. / Journal of Cystic Fibrosis 8 (2009) 405–417previous pancreatic enzyme therapy. Eligible patients then
entered a 7-day dose stabilization period, where they were
switched from their previous pancreatic enzyme therapy
(baseline) to EUR-1008 without a washout period. After the
completion of the dose titration/stabilization period, subjects
entered a 7-day treatment period with the study drug, with an
end of study evaluation occurring on the last day of treatment.
In the supplemental study, patient adherence to the CF diet
was assessed at the end of the dose stabilization and EUR-1008
treatment periods using patient dietary records (diary) kept by
the parents/guardians. Parents/guardians also recorded in the
diary all treatment doses, medication taken, the frequency and
characteristics of stools, and symptoms such as pain, bloating,
and flatulence during the study.
2.5. Evaluation of malabsorption signs and symptoms
In both studies, clinical signs and symptoms associated with
EPI were assessed by the investigator/research coordinator at the
study sites on the day of the study visit after the dose stabilization,
normalization (randomized study only), and treatment periods byevaluating stool characteristics (frequency, consistency, presence
of blood or oil/grease) and symptoms of pain, bloating, and
flatulence. Stool characteristics were evaluated by the investi-
gator/research coordinator by diary review and patient interview
on the day of the study visit, and by direct observation of the
stool samples collected at home and brought in for the study visit
(supplemental study only).
In the supplemental study, which required that patients be
without signs and symptoms of malabsorption to be considered
responders, patients were considered as being without signs and
symptoms of malabsorption if they had: hard, formed/normal, or
soft stools; no visible blood or oil/grease in stools; no symptoms
of abdominal pain; no or mild symptoms of bloating; and no or
mild symptoms of flatulence. In this study, physicians and
parents/guardians both evaluated patient symptoms by reviewing
parent/guardian observations of malabsorption as recorded in the
patient diary cards. EPI malabsorption symptoms were evaluated
according to the following measures: stool frequency; stool
consistency (hard, formed/normal, soft, watery, or overt diarrhea);
incidences of bloating, pain, and flatulence (graded as mild,
moderate, or severe); incidences of visible blood in stool; and
incidences of visible oil/grease in stool. At the conclusion of the
drug treatment period, physicians and parents/guardians eval-
uated the symptoms of EPI malabsorption as “unchanged,”
“improved,” or “worsened” as compared to the screening period,
representing the previous pancreatic enzyme therapy. Given the
design of the study, where patients were switched to EUR-1008
from a previous pancreatic enzyme therapy, “no change” from the
previous therapy was to be considered a positive outcome.
2.6. Stool collection and analysis
For stool collection and analysis in the randomized study,
patients were administered two 250 mg brilliant blue stool
markers to take with the first controlled meal of the inpatient
period, and the blue markers were re-administered at the
conclusion of the 72-hour controlled diet period. The first marked
stool was discarded, but all subsequent stool samples were saved
for analysis. At the appearance of the second stool marker, stool
collections stopped, remaining evaluations were completed, and
the patient was discharged.
The coefficient of fat absorption (CFA) was calculated as: [(fat
intake− fat excretion) / fat intake] ×100 over the 72 h following the
first appearance of blue dye in the stool. Fat intake was calculated
from the dietary record by a central dietitian who input the data into
The Food Processor SQL nutrition and fitness software (Version
9.6 [ESHA Research, Salem, OR]) to calculate fat excretion based
on dietary intake and 72-hour fecal collection. The fat content of
72-hour stool samples was determined by nuclear magnetic
resonance spectrometry [29] and the nitrogen content was deter-
mined by the Dumas combustion method.
In the supplemental study, spot fecal fat tests (acid steatocrit
method) were conducted at a central laboratory at screening, at the
completion of the dose stabilization period, and at the end of the 7-
day treatment period using a nuclear magnetic resonance spectro-
metry method [29]. The stool samples for fecal fat content were
collected at home (stored frozen). A value for steatorrhea of≥30%
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function as determined per a review of the literature [30–35]. The
baseline steatocrit taken during screening (representing treatment
with the patient's previous pancreatic enzyme therapy) was com-
pared to the dose stabilization and treatment measurements.
3. Efficacy assessments
The primary efficacy endpoint of the randomized study was
the change in the mean CFA between EUR-1008 and placebo,
which was measured from the 72-hour stool sample collected
during each inpatient hospitalization period. The key secondary
endpoint was the change in the coefficient of nitrogen absorption
(CNA) for EUR-1008 vs. placebo. Other secondary endpoints
included changes in: serum cholesterol, serum vitamins A and E,
body weight, BMI, and signs and symptoms of malabsorption
(stool frequency and consistency; bloating, pain, flatulence).
The primary efficacy endpoint in the supplemental study was
the percentage of “responders” to treatment with EUR-1008.
Responders were defined as those patients without steatorrhea
(b30% fecal fat content on a spot fecal fat test using the acid
steatocrit) and without signs and symptoms of malabsorption
after the dose stabilization and treatment periods. Patients were
considered non-responders if their steatocrit was ≥30% or they
showed signs and/or symptoms of malabsorption on the day of
the study visit.
Secondary efficacy measures in the supplemental study inclu-
ded: a) nutritional status (weight change) b) physician assessment
and parent/guardian observation of the control of EPI malabsorp-
tion symptoms from screening to the end of the study.
3.1. Safety assessments
Safety assessments in both studies included frequency, duration,
and severity of treatment-emergent adverse events (AEs) (any
event not present at baseline or any event already present that
worsened in intensity or frequency from baseline), as well as
clinical laboratory measurements, physical examination findings
(including monitoring for DIOS), and vital sign measurement.
Clinical laboratory measurements for the safety analysis included
tests for uric acid in serum and urine; serum chemistry,
hematology, and urinalysis; lipid profiles; and measurement of
fat-soluble vitamin (A and E) levels.
Health-related quality of life (QOL) was included in the safety
assessment of the randomized study only and was evaluated using
the Cystic Fibrosis Questionnaire-Revised (CFQ-R) appropriate
for the patient's age (bage 14 years, ≥age 14 years, and for
parents/caregivers of patients bage 14 years) at screening and at
the end of study visit.
All safety data was independently reviewed by the CFF
DSMB.
3.2. Laboratory testing
Measurement of fecal fat, fecal nitrogen (randomized study
only), serum lipids, and serum vitamin A and E levels was
performed at the Mayo Clinic Department of LaboratoryMedicine and Pathology (Rochester, MN). All other laboratory
analyses of blood, biochemistry, and urine in the supplemental
study were also performed at Mayo, while safety labs (chemistry,
hematology, and urinalysis) for the randomized study were
completed at the individual sites. Fecal elastase testing was
performed via a monoclonal assay by Genova Diagnostics, Inc.
(Asheville, NC).
3.3. Statistical methods
In the randomized study, the efficacy population (defined as all
randomized patientswith at least one post-baselinemeasurement in
each treatment period) was used in the analysis of the following
efficacy variables: CFA, CNA, and clinical symptoms of EPI. The
primary endpoint (comparison of mean CFA between EUR-1008
and placebo) and secondary efficacy variable (CNA) were
analyzed using an analysis of variance (ANOVA) model for
repeated measures. A repeated measures Poisson log-linear model
fitted using generalized estimating equations (GEE) was used to
analyze stool frequency and symptoms of bloating, flatulence, or
pain. AGEE repeatedmeasures logistic regressionmodel was used
to analyze the binomial proportion of stools of a specific
consistency, stools with macroscopically evident blood, and stools
with visible oil or grease.
The safety population consisted of all patients who received
at least one dose of study drug. Based on the recommendation of
the CF TDN Protocol Review Committee [36] and the CFF
DSMB [37], the secondary efficacy endpoints of serum total
cholesterol, calculated low-density and high-density lipoprotein
cholesterol (LDL-C, HDL-C), and fat-soluble vitamins were
analyzed using the safety population. Treatment group compar-
isons of mean change from screening were performed using a
paired t-test. As per the same recommendation, body weight and
BMI were summarized using the safety population.
A t-test for two independent samples was used to calculate the
sample size. A minimum sample of 30 (15 in each sequence)
patients would have provided 90% power to detect a 23% mean
difference in change in CFA at a two-sided alpha level of 0.05,
assuming a common standard deviation (SD) of 27% (nQuery
Advisor 4.0). A minimum sample size of 30 patients was also
required to obtain sufficient safety data.
In the supplemental study, data from all patients who received at
least one dose of the study drug were included in the analyses of
safety and efficacy. Safetywas evaluated in terms of the occurrence
and severity of AEs, as well as changes in clinical laboratory
parameters, physical examination findings, and vital sign measure-
ments. No interim analyses were performed, and no analyses were
required to correct for any baseline or center bias. Analyses of
change from baseline to the end of study for serum vitamins A and
E were done using the Wilcoxon matched pair signed rank test.
When the response was highly skewed or otherwise non-sym-
metric, the sign test for two related samples was used.
For the primary efficacy analysis of the supplemental study,
the percentage of responders between baseline and post-baseline
was compared using the McNemar test and presented with 95%
confidence interval and p-value. Change from baseline in fecal fat
content was analyzed using the Wilcoxon matched pair signed
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analyzed by the Wilcoxon signed rank test for continuous
variables and the McNemar test for categorical variables. Change
from baseline in stool frequency and number of severity-specific
bloating, pain, and flatus symptoms were analyzed by fitting a
repeated Poisson log-linear model using the GEE method. The
proportion of stools of a specific consistency, macroscopically
evident blood in stool, and visible oil/grease in stool were
analyzed by fitting a repeated logistic regression model using the
GEE method. Two-sided tests were used at a type I error rate of
0.05 for comparing values at baseline and 1 and 2 weeks after
EUR-1008 administration. No adjustment for type I error was
made for multiple comparisons.
P values in both studies were rounded to three decimal
places. All analyses were conducted using SAS Version 8.2 or
higher (SAS Institute Inc., Cary, NC).Table 1
Patient characteristics in the randomized trial (patients≥age 7years) and
supplemental study (patientsbage 7years).
Randomized trial
(N=32 a)
Supplemental study
(N=19)
Age (years)
Mean (±SD) 15.4 (±4.8) 3.9 (±1.6)
Range 8–23 1–6
Age in years by category, n (%)
≤3 years 0 9 (47.4)
4–5 years 0 7 (36.8)
6 years 0 3 (15.8)
7–13 years 7 (21.9) 0
14–17 years 12 (37.5) 0
N17 years 13 (40.6) 0
Sex, n (%)
Male 16 (50) 12 (63.2)
Female 16 (50) 7 (36.8)4. Results
4.1. Patient characteristics
Thirty-four patients were enrolled in the randomized study at
12 study sites across the United States. All received at least one
dose of the study drug and were included in the safety analyses
(Safety Population). One patient voluntarily withdrew consent
after dose titration/stabilization but before randomization, and one
patient received EUR-1008 through the randomization treatment
period and then voluntarily withdrew consent during open-label
normalization period 1; these patients were excluded from the
efficacy analysis. Therefore, 32 patients (mean age: 15.4 years)
were considered to have completed both treatment periods and
were included in the efficacy analysis (Efficacy Population).
Twenty-seven patients were screened for the supplemental
study. Seven of these patients did notmeet the inclusion/exclusion
criteria, and one patient was lost to follow up prior to receiving the
study drug. A total of 19 patients (mean age, 3.9 years) from ten
sites were enrolled and completed the study.
Baseline demographic characteristics for patients in both
studies are presented in Table 1.Race, n (%)
White 30 (93.8) 19 (100)
Other 2 (6.3) 0
Height (cm)
Mean (±SD) 154.8 (±18.1) 99.4 (±12.4)
Median 163.7 99.5
Range 114.8–176.0 76.5–121.8
Weight (kg)
Mean (±SD) 50.4 (±14.9) 16.6 (±3.8)
Median 55.7 15.8
Range 20.3–67.4 10.1–23.4
BMI (kg/m2)
Mean (SD) 20.4 (3.0) 16.7 (±1.4)
Median 20.3 16.4
Range 14.8–28.2 14.4–19.5
SD: standard deviation; BMI: body mass index.
a Efficacy Population, consisting of all patients who completed both
randomized, double-blind treatment periods.4.2. Drug exposure and dosage
The mean exposure to EUR-1008 in the randomized trial was
29.7 days (range, 19–42 days), while mean exposure to placebo
was 6.3 days (range, 4–10 days). Exposure to EUR-1008 in the
open-label, supplemental study was 14 days for all patients.
During the open-label dose titration/stabilization period of
the randomized study, the mean dosage (±SD) of EUR-1008
was 4591 lipase units/kg/day (±1555). The mean dosage of the
study drug was similar during blinded randomization
(4997 lipase units/kg/day [±1214]) and crossover treatment
(5715 lipase units/kg/day [±1648]), the first open-label normal-
ization (4469 lipase units/kg/day [±1420]), and the second
open-label normalization (3887 lipase units/kg/day [±1202]).
The mean drug compliance was 94.6% during treatment with
EUR-1008 for both double-blind treatment periods.In the supplemental study, the mean dosage (±SD) of EUR-
1008 administered during the dose stabilization period was
5094 lipase units/kg/day (±1774), and the mean dosage during
the treatment period was 5417 lipase units/kg/day (±1906).
4.3. Efficacy
In the randomized study, the estimated mean CFA and CNA
for patients treated with EUR-1008 was statistically significantly
higher (88.3% and 87.2%, respectively) than for patients treated
with placebo (62.8% and 65.7%, respectively) (pb0.001 for both
endpoints) (Table 2). For CFA, the mean difference between
EUR-1008 and placebo was 25.5% (95% CI: 19.3%, 31.7%),
while the mean difference for CNA was 21.5% (95% CI: 16.1%,
26.9%).
IndividualCFAvalues during placebo andEUR-1008 treatment
in the randomized study are illustrated in Fig. 3. Twenty-nine
patients (91%) achieved a CFA above 80% after treatment with
EUR-1008, with 16 (50%) of these patients achieving a CFA
Table 2
CFA and CNA with EUR-1008 and placebo (Efficacy Population).
EUR-1008
(N=32)
Placebo
(N=31 a)
CFA
LS means b (SEM) 88.3% (2.6) 62.8% (2.6)
p value c b0.001
CNA
LS means b (SEM) 87.2% (2.2) 65.7% (2.2)
p value c b0.001
CFA: coefficient of fat absorption; CNA: coefficient of nitrogen absorption;
SEM: standard error of the mean.
a One patient did not have fecal fat and nitrogen readings while on placebo.
b LS means (least-squares means) from an ANOVA model. LS means are
estimates of means that would be expected for a balanced design.
c P value for testing the null hypothesis: No difference between EUR-1008
and placebo based on an ANOVA model including main effects for treatment
and sequence and patient nested in sequence as a random effect.
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treatment attained a median increase of 51% in CFA while on
EUR-1008.
Compared to placebo, the clinical symptoms associated with
EPI improved during treatment with EUR-1008 in the rando-
mized study, according to information derived from patient/
guardian diary reports. This included a significant reduction in
stool frequency (1.8 vs. 2.7 stools/day, respectively; pb0.001);
fewer soft (29.2% vs. 57.1%; pb0.001) and watery (0.4% vs.
2.6%; p=0.013) stools; and an increase in stool consistency that
was noted as hard (16.3%vs. 6.2%; pb0.001) and formed/normal
(53.9% vs. 33.3%; pb0.001). No overt diarrhea was reported
while patients were taking EUR-1008.
During all treatment periods of the randomized study, the
incidence of bloating, pain, and flatulence, defined as a one-hour
block of time in which the patient experienced the symptom, was
low. For all severities of bloating, pain, and flatulence (mild,Fig. 3. Plots of the individual patient values of CFA during placebo and EUR-1008. B
standard error (SEM) of CFA during placebo (62.8±2.6%) vs. CFA during EUR-10
b100 µg/g stool at screening. CFA (coefficient of fat absorption); SEM (standard ermoderate, severe), there were fewer occurrences reported while
patients were receiving EUR-1008 than when receiving placebo.
Macroscopically evident blood in the stool was infrequent during
the study,with amean proportion of 0.2%during blinded treatment
with EUR-1008 and 1.1% during treatment with placebo. The
mean proportion of stool sampleswith visible oil or greasewas also
lower during treatment with EUR-1008 as compared to placebo
(6.8% vs. 28.0%; pb0.001), and there were statistically significant
differences in favor of EUR-1008 compared to placebo in themean
incidence of moderate flatulence (0.1 vs. 0.4; pb0.001), mild pain
(0.2 vs. 0.6; pb0.001), and severe pain (0.0 vs. 0.1; p=0.007).
The effect of EUR-1008 on reported signs and symptoms of
malabsorption remained consistent throughout all four treatment
periods of the randomized study (dose titration, active treatment,
and both open-label normalization periods). The improvements in
signs and symptoms associated with malabsorption were
observed regardless of CFA valueswhile on placebo and included
improvements in patients with CFA values N80% on placebo.
Post-hoc analyses in the randomized trial's safety population
for change from the screening period in total serum cholesterol,
HDL-cholesterol, and serum vitamins A and E showed a
statistically significant difference between EUR-1008 and
placebo (pb0.05 for all measures) (Table 3).
Treatment order (placebo→EUR-1008 or EUR-1008→pla-
cebo) did not appear to impact either time to normalization or
response to treatment.
In the supplemental study, 11 of 19 patients (57.9%) were
responders to EUR-1008 (i.e., b30% fecal fat content and without
signs and symptoms of malabsorption) at the end of the drug
treatment phase, compared to 10 of 19 (52.6%) at screening when
they were on their previous pancreatic enzyme therapy. Of the nine
patients who did not meet the criteria for “responder” at screening,
six responded to EUR-1008 by the end of the study, and five of the
10 patients who were classified as responders at screening
maintained their response with EUR-1008 treatment. Thears on the far left and right of figure indicate the least-squares (LS) means and the
08 treatment (88.3±2.6%). All patients had fecal elastase (monoclonal assay) of
ror of the mean).
Table 3
Change from screening in cholesterol and vitamin levels (Safety Population).
Screening End of treatment
All patients
(N=34)
EUR-1008
(N=33 a)
Placebo
(N=30 a)
Total cholesterol (mg/dL)
Mean (SD) 124.3 (29.5) 128.8 (30.0) 109.1 (29.8)
Mean change (SD) from
screening
4.0 (21.0) −16.1 (17.5)
p-value b b0.001
HDL (mg/dL)
Mean (SD) 42.4 (11.0) 45.5 (10.9) 37.2 (9.2)
Mean change (SD) from
screening
3.1 (8.1) −4.8 (7.7)
p-value b b0.001
Vitamin A (mcg/L)
Mean (SD) 380.9 (125.8) 422.3 (111.7) 363.2 (100.3)
Mean change (SD) from
screening
41.6 (89.4) −21.3 (98.6)
p-value b b0.001
Vitamin E (mg/L)
Mean (SD) 7.4 (4.1) 8.3 (3.1) 6.7 (2.7)
Mean change (SD) from
screening
0.76 (3.7) −0.94 (3.4)
p-value b b0.001
HDL: high-density lipoprotein.
For conversion of total cholesterol and HDL mg/dL to mmol/L: multiply by
0.026.
a One patient receiving EUR-1008 treatment and 4 patients in the placebo
treatment group failed to have a value noted in either the screening period or
during at least one of the two inpatient evaluation periods.
b P-values were calculated to compare mean change from screening; a paired
t-test was used to compare both treatment groups.
Table 4
Treatment-emergent adverse events (≥5%) during the randomization and
crossover treatment periods (Safety Population).
EUR-1008
(N=34)
Placebo
(N=32)
Total number of treatment-emergent AEs 43 43
Number of patients with ≥1 treatment-
emergent AE
19 (55.9%) 16 (50.0%)
Abdominal distension 2 (5.9%) 3 (9.4%)
Abdominal pain 4 (11.8%) 6 (18.8%)
Abnormal feces 1 (2.9%) 3 (9.4%)
Flatulence 2 (5.9%) 3 (9.4%)
Frequent bowel movements 1 (2.9%) 2 (6.3%)
Steatorrhea 0 4 (12.5%)
Early satiety 2 (5.9%) 0
Contusion 2 (5.9%) 0
Weight decreased 2 (5.9%) 2 (6.3%)
Headache 5 (14.7%) 0
Cough 2 (5.9%) 0
AE=adverse event.
Adverse events were coded according to MedDRA Version 8.1.
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1 week and 2 weeks of treatment with the study drug when
compared with the previous pancreatic enzyme therapy. These
results are consistent with the expected result that, in young CF
patients, EUR-1008 would be at least equivalent to patient's
previous PEP.
Secondary endpoint analyses based on patient diaries showed
that the incidences of EPI symptoms were low at all time points in
the supplemental study. Most patients reported fewer than three
incidences of symptoms per day, and patients experienced a
significant reduction in mean stool frequency (Pb0.001),
incidence of moderate bloating (P=0.011), and the proportion of
stool samples with visible oil or grease during treatment as
compared with screening (Pb0.001). All other secondary end-
points, including nutritional status, either maintained consistent
with baseline measurements or showed no statistically significant
changes.
None of the patients' clinical symptoms of EPI worsened
during the supplemental study based on the evaluation of patient
diary cards by study physicians and parents/guardians. Physicians
assessed 12/19 patients (63.2%) as having no change in the
control of EPI symptoms and 7/19 patients (36.8%) as having
improvements in the control of EPI symptoms after treatmentwith
EUR-1008. Parents/guardians judged 10/19 patients (52.6%) ashaving no change in EPI symptoms and 9/19 patients (47.4%) as
having symptom improvement by the end of the treatment period.
4.4. Safety
EUR-1008 was generally safe and well-tolerated in both
studies. There were no deaths during either study and no serious
adverse events (SAEs) related to the study drug. In addition, no
patients dropped out of either study due to an AE or laboratory
abnormality.
In the randomized study, the majority of AEs for both treatment
groups were mild (52%) or moderate (35%), and there were no
unexpected or significant differences in the frequency or type of
AEs between EUR-1008 and placebo. During the two one-week,
double-blind treatment periods, approximately equal numbers of
patients experienced at least one AE while receiving EUR-1008
(55.9%) compared to placebo (50.0%). The total number of
treatment-emergent AEs (events not present prior to study drug
exposure or those thatworsened in intensity or frequency following
drug exposure) was 43 for each of the double-blind treatment
periods (EUR-1008 and placebo). Treatment-emergent AEs
reported by the largest proportion of patients during the double-
blind treatment periods were abdominal pain, steatorrhea, and
headache (Table 4).
While receiving EUR-1008 or placebo, 47.1% and 37.5% of
patients, respectively, reported at least one AE that was considered
by the principal investigator at the study site to be possibly or
probably related to study drug. The most commonly reported
possibly or probably related AEs for either group were abdo-
minal pain, flatulence, abdominal distension, abnormal feces, and
steatorrhea.
Two EUR-1008 patients in the randomized study reported a
serious adverse event (SAE) (hemoptysis and acute exacerbation
of respiratory infection), both of which occurred during the dose
titration/stabilization period. Both SAEs resolved, and both were
considered by the investigators to be unrelated to the study drug.
414 J.L. Wooldridge et al. / Journal of Cystic Fibrosis 8 (2009) 405–417In the supplemental study, a total of 51 treatment-emergent AEs
were reported by 13 patients. Of these, 17 events (33.3%) reported
by 5 patients were considered by the investigator to be possibly
related to the study drug (Table 5). The most frequently reported
AEs included abdominal pain, steatorrhea, feces discolored,
flatulence, vomiting, abdominal discomfort, abdominal distention,
and diarrhea, and were mild or moderate in severity. Two patients
reported severeAEs (1 abdominal pain and 1 flatulence); bothwere
considered possibly related to the study drug. Both events resolved
in one day without treatment or discontinuation of the study drug.
One patient experienced an SAEof upper respiratory tract infection
that was deemed by the investigator secondary to CF and not
related to study drug.
In both studies, there were no unexpected adverse trends
identified in the routine safety labs of serum chemistry, hema-
tology, and urinalysis following treatment with EUR-1008, nor
were there any noteworthy changes in vital signs, physical
examinations, weight, BMI, or QOL assessments as compared to
baseline. In addition, no uric acid toxicity or fibrosing colonopathy
was reported during either study, and there was no change in serum
uric acid levels compared to placebo.
5. Discussion
The measurement of CFA on a 72-hour stool sample collected
in a controlled environment is the current “gold standard” for
evaluating the efficacy of enzyme replacement therapy in patients
with EPI [38]. In the randomized, double-blind, placebo-con-
trolled trial, mean fat absorption as measured by CFA was
significantly higher during treatment with EUR-1008 than with
placebo. Moreover, patients were more likely to achieve mean
CFA levels N85%, representing “near-normal” CFA values [39],
during EUR-1008 treatment as compared with placebo, and CNA
was also significantly improved during treatment with the study
drug as compared to placebo.
The findings of the randomized study support the known
benefits of PEPs in managing malabsorption in patients with CF.Table 5
Adverse events related to the study drug (patients b7 years of age) EUR-1008
(N=19).
Not related
(N=8)
Related
(N=5)
Possible Probable Definite
Total number of AEs 34 (66.7%) 17 (33.3%) 0 0
Gastrointestinal disorders 3 (15.8%) 5 (26.3%) 0 0
Abdominal distension 0 1 (5.3%) 0 0
Abdominal pain 1 (5.3%) 4 (21.1%) 0 0
Feces discolored 1 (5.3%) 1 (5.3%) 0 0
Flatulence 0 2 (10.5%) 0 0
Steatorrhea 1 (5.3%) 2 (10.5%) 0 0
Metabolism and nutrition
disorders
1 (5.3%) 1 (5.3%) 0 0
Decreased appetite 0 1 (5.3%) 0 0
AE=Adverse event.
Note: AEs are listed by system organ class preferred term. The total number of
AEs includes all AEs for patients.Mischler and colleagues reported that enteric-coated pancrelipase
improved both CFA (84.1% on treatment vs. 45.7% placebo;
pb0.005) and CNA (83.3% on treatment vs. 64.3% placebo;
pb0.01) [40]. A study of supplemental pancreatic enzyme therapy
by Konstan et al. compared two doses of pancrelipase (12,000 and
20,000 lipase units per capsule) to placebo [41]. Mean CFA and
CNA was 79.4% and 83.8%, respectively, for the low-dose
pancrelipase group, compared to 46.7% (p=0.0002) and 58.4%
(p=0.0001), respectively, for placebo; mean CFA and CNA was
87.3% and 88.6%, respectively, for the high-dose pancrelipase
group, versus 58.7% (p=0.0001) and 62.9% (p=0.0001),
respectively, for placebo. In an open-label study by Stern et al. in
which patients with CF and EPI received treatment for ≥6 days
with delayed-release enteric-coated pancrelipase or placebo, mean
CFA was 84.1% with pancrelipase treatment compared to 52.2%
with placebo among patients age 7 to 18 years [42]. Finally, a
prospective, randomized, controlled trial by Brady et al. found that
patients receiving enteric-coated high-buffered pancrelipase had a
mean CFA of 81.8% vs. 75.1% for enteric-coated-nonbuffered
enzymes (P=0.01) [43].
The majority of patients reached normal or near-normal levels
of CFA and CNA in the randomized trial while on EUR-1008
treatment, with improvement in CFA and CNA proportionately
greater in patients with lower values on placebo. A similar rela-
tionship was observed in a dose-ranging study of ALTU-135, with
the greatest improvements seen in subjects with baseline CFA and
CNA b40% [44]. Notably, the improvements observed in the
present study were achieved in the absence of any concomitant
treatment affecting gastrointestinal motility or pH, suggesting that
EUR-1008 alone may be as efficacious as other products that have
been tested with concurrent gastrointestinal agents.
Although CFA measurement is considered the most reliable
assessment of fecal fat content, it requires that the 72-hour stool
collection be performed in a hospital setting, which is inconvenient
and poses some risks to CF patients who are prone to infections. In
addition, stool collection for measurement of CFA in young
children who may still wear diapers is cumbersome and provides
unreliable results, as the stool must be scraped from the diaper liner
for analysis. Therefore, the primary efficacy endpoint selected for
the supplemental study relied on the spot fecal fat test from a single
stool sample to assess steatorrhea. This is considered a valid
method for assessing fecal fat content [30–35] and was selected
based upon a review of the literature and input from the inves-
tigators and the CFF-TDN.
The definition of responder used in the supplemental trial (i.e.,
b30% fecal fat content and without signs and symptoms of
malabsorption) essentially corresponds to “normal” subjects in
terms of pancreatic function, and is therefore an efficacy endpoint
with a challenging threshold. Nevertheless, the results obtained at
screening (when patients were on their previous pancreatic enzyme
therapy) and after treatment with EUR-1008 were similar,
suggesting a consistent response. Furthermore, patients had
improvement in some symptoms of malabsorption after treatment
with EUR-1008 (e.g., reduction of stool frequency, bloating, and
stool with visible oil or grease). In addition, EUR-1008 maintained
patients' control of malabsorption using doses similar to the
patients' previous pancreatic enzyme therapy and did not
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by physicians and parents/guardians upon review of patient diary
cards to maintain or improve the control of EPI signs and
symptoms vs. previous pancreatic enzyme therapies. No physician
or parent/guardian assessed patients' symptoms as having wor-
sened during the study.
In both studies, EUR-1008 was associated with clinically
significant improvements in the signs and symptoms associated
with EPI malabsorption in both young children and adults.
Similar improvements in the signs and symptoms of malabsorp-
tion were observed by Stern and colleagues in an open-label
study that demonstrated that pancrelipase mini-microspheres
significantly decreased stool frequency and the incidence of soft
stools [42]. Notably, the efficacy of EUR-1008 was achieved
using a dose of lipase units consistent with the label claim (i.e.,
no enzyme overfill).
EUR-1008 was safe and well-tolerated in both studies. No
patients dropped out of either study due to an AE. In the
randomized trial, study drug compliance was 94.6%. The two
observed SAEs in the randomized trial, hemoptysis and
worsening lung disease, were assessed to be unrelated to the
study drug and both resolved. There were no unexpected or
significant differences in the number of AEs between EUR-1008
and placebo during the two efficacy evaluation periods, nor were
there significant changes in laboratory safety values. The most
commonly reported possibly or probably related AEs reported for
EUR-1008 and placebo (abdominal pain, flatulence, abdominal
distension, abnormal feces, and steatorrhea) are consistent with
the background disease. Headache, which is reported regardless
of causality, was observed during the randomized treatment
period in 14.7% of patients receiving EUR-1008, but was not
reported in any patients during treatment with placebo. The cause
of headache while patients were on treatment is unknown;
however, CFpatients frequently have sinus disease and associated
headache, which may help explain this finding. In the supple-
mental study in young patients, only two AEs possibly related to
the study drug were reported as severe (1 event of abdominal pain
and 1 event of flatulence), and both resolved in one day without
treatment. There were no drug-related SAEs or discontinuations,
nor were there any incidences of hyperuricemia or unexpected
adverse trends in laboratory analyses following treatment with
EUR-1008. As with previous studies of PEPs in young children
[22–26], no age-related issues were noted with EUR-1008.
However, these safety data may be limited by the short length of
the study period (two weeks), which is too brief to detect AEs
such as fibrosing colonopathy (not observed in this study).
Due to the young age of the patient population studied in the
supplemental study, a number of challenges related to the choice
of study controls and efficacy endpoints had to be addressed, and
the design of the study was extensively discussed among the
sponsor, the investigators, the CFF-TDN, and the FDA. Owing to
ethical concerns about patient health and discomfort, it was
considered inappropriate to remove the young children enrolled in
this trial from EPI medications. Therefore, this trial did not
employ a washout period or placebo control, as a lack of active
treatment could lead to compromised nutritional status and
considerable weight loss in this young patient population. This issignificant, as weight loss during infancy or childhood correlates
with poor adult pulmonary status in CF patients [5–11]. The
decision to not use a placebo treatment or washout period in the
design of the supplemental study is consistent with the practice
reported in other published trials involving young CF patients
[22–26].
In the supplemental study, EUR-1008 was effective in
controlling fat malabsorption in a manner consistent with patients'
previous pancreatic enzyme therapies. These results suggest that
young children on PEP treatments can be rapidly and successfully
switched to this new drug and obtain the benefits of a PEP
formulated to meet the lipase label claim. In addition, this
formulation of EUR-1008 was specifically developed for use in
young children and allows the contents of the capsule to be
sprinkled on foods such as applesauce and banana pudding, when
necessary, allowing for convenience of administration.
In summary, EUR-1008, a new PEP for the treatment of EPI
formulated to meet the label-claimed lipase enzyme content, was
safe, effective and well tolerated in two clinical trials designed to
meet FDA guidelines for PEPs, including demonstration of safety
and efficacy endpoints that support the use of EUR-1008 for the
treatment of EPI-associated malabsorption in both younger and
older CF patients.
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